Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on October 10, 2025. The filing was submitted to the SEC on October 13, 2025. The transaction was executed by BNP Paribas SA acting as the broker under a non-discretionary agreement announced on September 30, 2025, as part of the Company's existing share buyback programme.
Key Financial Metrics and Transaction Details
The filing details a specific repurchase of ordinary shares with a nominal value of 31½ pence each. The purchased shares are held as Treasury shares.
- Shares Purchased (Oct 10): 355,000 ordinary shares
- Lowest Price Paid: 1,623.00 GBp
- Highest Price Paid: 1,646.00 GBp
- Volume-Weighted Average Price (VWAP): 1,635.50 GBp
- Trading Venues: London Stock Exchange (XLON), CHIX, and BATE
Cumulative Activity: Since September 30, 2025, the Company has purchased a total of 2,904,000 ordinary shares.
Capital Structure Post-Transaction:
- Treasury Shares Held: 250,368,844
- Ordinary Shares in Issue (excluding Treasury): 4,065,044,985
- Total Voting Rights: 4,065,044,985
- Treasury Voting Rights Percentage: 6.16%
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury holdings resulting from the October 10 repurchase. The filing does not provide comparative financial performance data (revenue, profit, cash flow) for the period, as this is a transaction-specific disclosure rather than a periodic financial report.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the Company's Annual Report on Form 20-F for 2024 and its Q2 Results for 2025. No new guidance or management commentary regarding operational outlook is provided in this document.
Investor Verification Checklist
- Verify the total number of shares in issue (4,065,044,985) for accurate calculation of ownership percentages under FCA Disclosure Guidance and Transparency Rules.
- Confirm the 6.16% voting rights attributable to treasury shares to assess potential dilution or voting power dynamics.
- Review the non-discretionary agreement terms announced on September 30, 2025, to understand the remaining scope of the buyback programme.
- Check the referenced Form 20-F (2024) and Q2 2025 results for detailed risk factors and financial performance context not included in this transaction report.